Acute decompensated heart failure. Acute systolic (congestive) heart failure
Conditions
Interventions
Intervention 1: Intervention group: Initial dose (loading) of 2 mg of colchicine (manufactured by Darou Pakhsh Company, Tehran, Iran) is received at the time of emergency admission and then a maintena
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Acute heart failure based on signs and symptoms and echo in the emergency room Presence of clinical and radiological evidence of congestion
Exclusion criteria
Exclusion criteria: Inflammatory bowel disease, chronic diarrhea, or malabsorption disease severe gastrointestinal illness Peptic ulcer Rheumatic inflammatory disease Neuromuscular disease Hematological disease Severe and recurrent arrhythmia Cirrhosis or active, chronic liver disease Patients currently taking Colchicine for another indication Severe valvular heart disease COPD GFR < 30 Hypersensitivity to colchicine Chronic treatment with Immunosuppressive drugs, steroids, or IL1 antagonists Pregnancy or breastfeeding Life expectancy less than 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The quality of life. Timepoint: Upon discharge - two months after discharge. Method of measurement: McNew Quality of Life Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe Motamedi
Qazvin University of Medical Sciences
Outcome results
None listed